In Brief: Endocrinologic & Metabolic Drugs Advisory Committee
Executive Summary
Endocrinologic & Metabolic Drugs Advisory Committee: Two-day meeting is scheduled for Feb. 23 and 24. The committee will discuss Serono's Geref (sermorelin acetate, NDA 20-443) for growth hormone insufficiency on Feb. 23. Roussel Uclaf's NDA 20-169 for Anandron (nilutamide) for prostate cancer will be discussed Feb. 24. The meeting will begin at 8:30 a.m. both days at the Holiday Inn Silver Spring, Md...
|
Endocrinologic & Metabolic Drugs Advisory Committee: Two-day meeting is scheduled for Feb. 23 and 24. The committee will discuss Serono's Geref (sermorelin acetate, NDA 20-443) for growth hormone insufficiency on Feb. 23. Roussel Uclaf's NDA 20-169 for Anandron (nilutamide) for prostate cancer will be discussed Feb. 24. The meeting will begin at 8:30 a.m. both days at the Holiday Inn Silver Spring, Md.... |